Expert Review in Renal Cell Carcinoma (RCC) |
Lee Lokey, MD, senior medical director of prIME Oncology, conducts expert interviews with Camillo Porta, MD, and Brian I. Rini, MD, focusing on the recent advances in the field of renal cell carcinoma. |
 |  | Discussant:
Brian I. Rini, MD
Cleveland Clinic Taussig Cancer Institute,
Cleveland, Ohio, United States |
|---|
|  | Discussant:
Camillo Porta, MD
IRCCS San Matteo University Hospital Foundation,
Pavia, Italy |
|---|
|
Learning Objectives | After successful completion of this activity, participants should be able to:
- Understand the biology of renal cell carcinoma (RCC) including growth factor alterations
- Describe the rationale for targeting vascular endothelial growth factor (VEGF) in the management of metastatic RCC
- Compare and contrast strategies for targeting VEGF and related mechanisms of action
- Discuss standard and investigational approaches to sequential therapy for metastatic RCC
|
Discussion Topics |
- Rationale for targeting VEGF and the evidence for the continued reliance of RCC tumors on VEGF signaling
- Current standards for initial therapy for metastatic RCC
- Standards of care for progressive disease or drug intolerance following first-line and second-line therapy
- Recent information and data regarding feasibility and therapeutic impact of sequential anti-VEGF therapy
|
|
|
|
Activity Date | This Webcast is available from 28 March 2011 to 28 March 2012. |
Audience | The information on this site is intended for all healthcare professionals based outside of the United States. You will be asked to provide your credentials before accessing the Webcast and slides. This site may contain information on products outside the approved indications where you practice. |
Support | This educational activity is supported by Bayer Healthcare.
|
|
